More Stories

Informist, Friday, Fri. 06, 2026

MUMBAI – The Nifty Pharma index is expected to remain range-bound next week as the market awaits details on the recently announced India-US trade deal agreement, under which the US has brought down tariffs on India to 18% from the current 50%. Pharmaceutical exports to the US are currently exempted, but more details on the trade deal are required to assess its impact on the Indian pharmaceutical players, according to analysts.

The December quarter earnings of Sun Pharmaceuticals, Dr. Reddy's Laboratories, and Cipla were disappointing as most companies reported weak sales in their generics segment. The results induced caution among market participants, who will closely watch earnings of other drugmakers for cues.

However, the recent data from IQVIA may lend some positive cues to investors. Data from IQVIA shows that Sun Pharma's specialty segment is doing well, with a growth of 9.5% in the three months ended December. The company's key products such as Ilumya and Odomzo are performing well, and they're gaining market share. However, its generics segment faces challenges, especially with the US Food and Drug Administration's inspection at the Baska injectable site, which might impact the company's US generics business in the short term.

Dr. Reddy's is maintaining its market share in some key generic products, but it is facing tough competition in products like Iron Sucrose and Octreotide LAR. Cipla's Albuterol market share is slightly down, and it is facing increased competition in Abraxane.

The Nifty Pharma index is likely to find support around 21200 points and the resistance for the index is pegged at 22150 levels, according to a technical analyst. For the week ended Friday, the Nifty Pharma index ended over 1% higher at 21961.35 points. Sun Pharmaceutical Industries was the biggest gainer during the week, rising over 6% at INR 1,695.10, followed by Piramal Pharma, which rose nearly 3% at INR 158.75. Glenmark Pharmaceuticals ended lower by a little over 4% at INR 1,934.80, and IPCA Laboratories fell nearly 4% to close at INR 1,416.70, on the National Stock Exchange. 

TOP HEADLINES

* Zydus Life's Desidustat gets 'orphan drug designation' from US FDA
* Jubilant Pharmova Oct-Dec consol PAT falls 44.6% YoY to INR 559 million
* Analyst Concall:Capacity addition to aid earnings going forward: Max Health
* Alembic Pharma gets US FDA final OK for Carbidopa, Levodopa, Entacapone drugs
* Gland Pharma gets US FDA OK for Zoledronic Acid injection single-dose bags
* JB Chem names Kaushal Solanki as CFO; gives INR 12.7/shr interim dividend
* Sai Life Sciences Oct-Dec consol PAT rises over 86% YoY to INR 1 billion
* Maharashtra GST authorities initiate search at Cipla's offices
* Earnings Review: Max Health misses Q3 view on low occupancy, one-time costs
* Alembic Pharma Oct-Dec consol PAT falls 3.9% YoY to INR 1.33 billion
* Caplin Point Labs Oct-Dec consol PAT rises 17.9% YoY to INR 1.64 billion
* Piramal Pharma gets state pollution control board notice to shut Gujarat unit
* Lupin launches seizure, migraine drug Topiramate in US post FDA nod
* Cohance Lifesciences' Hyderabad unit gets warning letter from US FDA
* Zydus Life gets tentative approval from US FDA for Dapagliflozin tablets
* Emcure Pharma Oct-Dec consol PAT rises 50% YoY to INR 2.31 billion
* HC allows Natco Pharma to manufacture semaglutide, export to some nations
* Analyst Concall: Mankind Pharma on track to launch GLP-1 product in March
* Earnings Review: Mankind Pharma Q3 PAT misses Street's view on one-time cost
* NATCO Pharma gets US FDA's tentative approval for Erdafitinib tablets
* US tariff cut credit positive for India's labour-intensive sectors - Moody's
* HC notice to JBD Life on Dr Reddy's plea for cancelling 'rozatan' trademark
* Aarti Industries Oct-Dec PAT rises nearly three-fold YoY to INR 1.31 bln
* HC bars Dabur from selling oil similar in trade dress to Emami's Navratna
* SC to decide if CCI can examine antitrust cases arising out of patent rights
* Lupin launches Dasatinib tablets in US after US FDA approval
* Lupin joins TB Alliance for development, commercialisation of Telacebec
* Analyst Concall: Glenmark Pharma sees 7-8 new pdts driving growth next 5 yrs
* BUDGET: Proposes INR 100 bln outlay for Biopharma SHAKTI for 5 years
* Analyst Concall:Sun Pharma to launch semaglutide in Mar, recruit sales staff
* AstraZeneca Pharma gets govt nod to import Durvalumab for gastric patients
* Earnings Review: Sun Pharma Q3 consol PAT beats view on all-round growth
* Earnings Review:Sun Pharma Q3 consol PAT beats view on all-round growth
* Pharma Stocks Outlook: Fundamental outlook strong on India-EU deal
* Earnings Review: Growth across mkts lifts Glenmark Pharma Q3 consol PAT
* MedPlus Health Oct-Dec consol PAT rises 26% on year to INR 578.07 million
* Ajanta Pharma Oct-Dec consol PAT rises nearly 18% YoY to INR 2.74 billion

Following are the resistance and support levels for key pharmaceutical stocks for next week as per calculations based on their prices on the National Stock Exchange:

End

Reported by P. Madhu Kumar

Edited by Tanima Banerjee

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000/+91 (11) 4220-1000

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2026. All rights reserved.